A Randomized, Multicenter, Phase III Study to Compare 6 Months of either 5-Fluorouracil / l-leucovorin plus Oxaliplatin (mFOLFOX6) or Capecitabine plus Oxaliplatin (XELOX) with 3 Months of either mFOLFOX6 or XELOX as Adjuvant Chemotherapy in Patients with Completely Resected Stage III Colon Cancer
Latest Information Update: 23 Jun 2022
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ACHIEVE
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.
- 12 Aug 2021 Results (n=1379) assessing single-nucleotide polymorphisms predicting L-OHP-induced PSN using a genome-wide association study approach from two clinical studies: JOIN-JFMC41 and ACHIEVE-JFMC47 published in the Annals of Oncology
- 17 Jan 2021 Results (n=1805) of ACHIEVE and ACHIEVE-2 trials assessing clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer, presented at the 2021 Gastrointestinal Cancers Symposium